Lightnews — Scholar-powered news

Gedeptin in New Solid Tumors

January 22, 2026 at 6:55 PM

John Vandermosten

@vanjohn10.bsky.social

GeoVax is developing its Gedeptin Gene-Directed Enzyme Prodrug Therapy, which is a type of targeted chemotherapy & gene therapy, which it is using in combination with checkpoint inhibitors. CEO David Dodd looks @ solid tumors where Gedeptin has shown promise. #biotech
#$GOVX
youtu.be/akLYO-8Tl0U

IFx-2.0 Phase II in Deep Seated Tumors

January 21, 2026 at 6:17 PM

John Vandermosten

@vanjohn10.bsky.social

TuHURA Biosciences' CEO Dr. James Bianco explains how IFx-2.0 may work in other solid tumors besides Merkel cell carcinoma & show synergy with checkpoint inhibitors.
#$HURA
#ImmunoOncology #CancerResearch #Oncology #BioTech #LifeSciences
youtube.com/shorts/62SOT...

GeoVax Highlights 2026 as a Pivotal Year for Progress

January 20, 2026 at 7:51 PM

John Vandermosten

@vanjohn10.bsky.social

GeoVax press release highlights multiple 2026 drivers:
*Clinical readouts GEO-CM04S1 (COVID)
*Gedeptin Ph2 launch
*Smallpox/Mpox Ph3 & US sourcing of vaccine
#$GOVX
finance.yahoo.com/news/geovax-...

Management Highlights 2026 as a Portfolio-Wide Inflection Year Driven by Regulatory De-Risking, Clinical Readouts, and Scalable Manufacturing ATLANTA, GA - January 20, 2026 (NEWMEDIAWIRE) - GeoVax Lab...

How Does the Delta Opioid Receptor Work?

January 20, 2026 at 2:32 PM

John Vandermosten

@vanjohn10.bsky.social

TuHURA CEO Dr James Bianco explains how the delta opioid receptor (DOR) works and the way in which it affects immune system response
#$HURA
#MDSCs #ImmunoOncology #CancerResearch #CancerTreatment #Oncology
youtube.com/shorts/eE8x8...

January 19, 2026 at 5:36 PM

John Vandermosten

@vanjohn10.bsky.social

After a vaccine receives approval, there are still hurdles to overcome before administration. We look at some of the new technologies including portable refrigerators, new battery technology & drones. GeoVax CEO David Dodd shares his thoughts on the topic. #$GOVX
youtu.be/10ylZjTHrNo

Vaccine Distribution

January 19, 2026 at 12:16 AM

John Vandermosten

@vanjohn10.bsky.social

Dr Bianco introduces TuHURA’s Immune Modulating ADCs which link a VISTA inhibitor to a delta opioid receptor inhibitor to target the tumor microenvironment rather than the tumor itself
#$HURA
#TumorMicroenvironment #ImmunoOncology #MDSCs #MyeloidCells #VISTA #Oncology #ADC youtube.com/shorts/jfTnJ...

Immune Modulating ADCs

Three Re emerging Pathogens

January 16, 2026 at 2:56 PM

John Vandermosten

@vanjohn10.bsky.social

GeoVax CEO David Dodd attended several conferences in Europe in 2H25 & heard concerns from stakeholders regarding a resurgence in previously considered eradicated viruses. We review measles, polio & whooping cough.
$GOVX
#biotech #biotechnology #science #GeoVax #Vaccines
youtu.be/QMri80C_A8s

January 15, 2026 at 3:37 PM

John Vandermosten

@vanjohn10.bsky.social

Jazz Pharma sells FDA's Priority Review Voucher to undisclosed buyer for $200mm. The PRV was related to rare pediatric disease drug Modeyso.
PRV prices have ranged from $68-$350mm over the last 12 years.
$JAZZ
www.firstwordpharma.com/story/7064821

www.firstwordpharma.com

January 15, 2026 at 1:49 PM

John Vandermosten

@vanjohn10.bsky.social

TuHURA Bio developed an SPA guided by the FDA's Project Frontrunner to advance promising therapies. CEO Bianco explains the process & the resulting efficient trial design that allows for both accelerated & full approval. $HURA
#Bioscience #LifeSciences #Oncology youtube.com/shorts/lcHe9...

IFx 2 0 Trial Design

Travere Therapeutics Provides Corporate Update and 2026 Outlook

January 14, 2026 at 4:45 PM

John Vandermosten

@vanjohn10.bsky.social

$LGND Ligand shares down 11% today on a delay in Travere's Filspari approval timeline. FDA requesting more info for the FSGS indication right before PDUFA date. At best it is a delay. Our model and valuation do not include a contribution from FSGS. Biospace reporting www.biospace.com/press-releas...

www.biospace.com

January 13, 2026 at 3:51 PM

John Vandermosten

@vanjohn10.bsky.social

A lyophilized version of the smallpox vaccine was recently approved by the FDA. GeoVax also expects to have a freeze dried version of the vaccine after approval. This formulation is useful in developing regions & for storage. CEO David Dodd shares his thoughts.
$GOVX
youtu.be/KTjMXmpZoK0

Lyophilized Mpox Vaccine

Lexaria Releases Annual Letter from the CEO - Lexaria Bioscience

January 13, 2026 at 2:27 PM

John Vandermosten

@vanjohn10.bsky.social

Lexaria CEO pens annual shareholder letter
*progress on GLP1 studies
~DHT shows improved adverse events
~effective in market with few oral options
*2026 priority remains GLP1 & MTA partner relationship
*designing next GLP1 study
*other biz dev in place
$LEXX
lexariabioscience.com/2026/01/12/l...

KELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provi...

lexariabioscience.com

January 12, 2026 at 3:27 PM

John Vandermosten

@vanjohn10.bsky.social

Achieve Life Sciences appoints Dr Mark Rubinstein as permanent Chief Medical Officer. Prior to $ACHV, he was Head of Medical Affairs at Blip where he led a strategy to support smoking & vaping cessation.
finance.yahoo.com/news/achieve...

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...

Immune Tolerance and the Delta Opioid Receptor

January 12, 2026 at 3:18 PM

John Vandermosten

@vanjohn10.bsky.social

Tuhura Biosciences CEO Dr Bianco explains the delta opioid receptor's mechanism & how its inhibition can allow the immune system and other agents to fight cancer. $HURA
#LifeSciences #Oncology
youtube.com/shorts/lWAhB...

RAD Increases Ownership in Radiopharm Ventures to 87.5%

January 12, 2026 at 1:45 PM

John Vandermosten

@vanjohn10.bsky.social

Radiopharm Theranostics increases ownership in Radiopharm Ventures to 87.5%-a JV with MD Anderson for advancing Betabart (RV01). The Lu-177, B7H3 targeting antibody is the subject of a Ph1 study in solid tumors.
$RADX
finance.yahoo.com/news/rad-inc...

Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received...

Delta Opioid Receptor Role in Immunosuppression

January 12, 2026 at 1:18 PM

John Vandermosten

@vanjohn10.bsky.social

Dr Bianco explains the mechanism behind immunosuppression which is impacted by FOXP3's control of Tregs. TuHURA has identified the Delta Opioid Receptor as the switch that can modulate immune cell function. $HURA
youtube.com/shorts/ETegB...

Legislators & Domestic Vaccine Manufacture

January 10, 2026 at 6:00 PM

John Vandermosten

@vanjohn10.bsky.social

Where is the US government willing to invest in the biopharma space? GeoVax Labs CEO David A. Dodd explains which technologies make the most sense to support with funding.
$GOVX
www.youtube.com/watch?v=tOgs...

A single, interpretable vocal biomarker for enriching antipsychotic clinical trials

www.youtube.com

January 9, 2026 at 2:42 PM

John Vandermosten

@vanjohn10.bsky.social

Reviva Pharmaceuticals publishes RECOVER vocal biomarker data in Biological Psychiatry
*A Single, Interpretable Vocal Biomarker for Enriching Antipsychotic Clinical Trials
www.biologicalpsychiatryjournal.com/article/S000...
$RVPH
finance.yahoo.com/news/reviva-...

Speech latency, an objective measure of verbal response time, is sensitive to cognitive, social, and motivational factors, and can be measured using recordings of psychiatric interviews. Emerging evid...

www.biologicalpsychiatryjournal.com

January 8, 2026 at 7:48 PM

John Vandermosten

@vanjohn10.bsky.social

CEO Dr Bianco shares TuHURA's work with the #FDA's Oncology Center of Excellence to construct a trial to satisfy requirements for accelerated & full approval of IFx-2.0 in Merkel Cell Carcinoma
$HURA
#TuhuraBio #Bioscience #LifeSciences #Oncology #TargetedTherapies
youtube.com/shorts/eeS09...

IFx 2.0 Trial Design

Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

January 8, 2026 at 7:27 PM

John Vandermosten

@vanjohn10.bsky.social

The Delta Opioid Receptor & Nobel Prize Discovery:
TuHURA Biosciences CEO Dr James Bianco joins us to talk about work $HURA has done to better understand the delta opioid receptor. Findings tie into the 2025 #NobelPrize in medicine that made discoveries in peripheral immune tolerance. #oncology

January 7, 2026 at 9:31 PM

John Vandermosten

@vanjohn10.bsky.social

Azitra's COO Travis Whitfill to present at Biotech Showcase next week.
*13Jan26
*Hilton SFO Union Square
$AZTR
finance.yahoo.com/news/azitra-...

Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at ...

Protalix BioTherapeutics Letter to Stockholders | Protalix BioTherapeutics

January 7, 2026 at 1:35 PM

John Vandermosten

@vanjohn10.bsky.social

Protalix CEO Dror Bashan pens letter to stockholders emphasizing:
*Development
~Ph2 PRX115
~Renal pipeline-PRX119
~Secarna OligoCreator
*Chiesi, Elfabrio & CHMP flexible dosing
*Dec'25 BioMarin/Amicus Galafold acq
*Elelyso
$PLX
ir.protalix.com/news-release...

ir.protalix.com

January 5, 2026 at 2:20 PM

John Vandermosten

@vanjohn10.bsky.social

@lantheus.bsky.social closes SPECT business sale to SHINE Technologies
*Includes Technelite, Neurolite, Xenon Gas & Cardiolite
$LNTH
finance.yahoo.com/news/lantheu...

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians ...